IDH Raises the Bar on Itself — and Decides to Keep the Cash

A 37% margin guide, a suddenly national branch network, and an accelerated Saudi plan — offset by a dividend that quietly didn't happen

IDHC.L · Earnings Call · 2026-09-15

A Guidance Reset, Not a Routine Beat

Integrated Diagnostics Holdings walked into its H1 2026 call with a strong print and then did something rarer: it guided above its own half-year run-rate. Revenue rose 37% year-on-year to EGP 4.9bn, tests performed climbed 20% to 23.6 million, and revenue per test rose 14% to EGP 206. Gross profit grew 41% to EGP 2.1bn on a 43.3% margin (up from 42%), EBITDA rose 38% to EGP 1.6bn at a 33.9% margin, and net profit jumped 47% to EGP 839m. Then the punchline: “We are forecasting a revenue of EGP 11 billion, gross profit of 46%, EBITDA margin of 37%, and net profit margin of 20%.” — Hend El Sherbini, Chief Executive Officer · 2026-09-15 That is a genuine step-change against the plan management sold in April, when the CFO's predecessor-style framing was “an increase of 25% on sales, a 10% increase in prices and 15% from volume. We're keeping an EBITDA of range -- same range of EBITDA of around 33% to 34%.” — Tarek Yehia, Head of Investor Relations · 2026-04-21 Moving the EBITDA anchor from ~33-34% to 37% and the net margin to 20% is the single most important fact in this report — it says H1's margin was structural, not seasonal, and management believes strong operating leverage carries into a seasonally better H2.

The Egypt Flywheel and Saudi Optionality

Egypt did the heavy lifting: revenue +41% to EGP 4.2bn, or 86% of the group. The mechanism is worth understanding because it changes the cost model. Growth is no longer just owned branches — it is embedded labs inside hospitals and clinics, which is why the footprint jumped by 157 sites in twelve months to 793 locations. As the CEO put it, “We're looking at around 50 more branches in H2 in Egypt.” — Hend El Sherbini, Chief Executive Officer · 2026-09-15 Management ran 20 hospitals and 49 clinics on a revenue-share basis, so expansion capital is someone else's problem. The second engine is radiotherapy platform scaling: radiology and radiotherapy revenue reached EGP 220m, up 79%, spanning nine branches. And then Saudi Arabia, where the arithmetic has quietly been re-based. In November the plan was “After 5 years for the 5-year plan for Saudi to represent 7% from the group revenue” — Tarek Yehia, Head of Investor Relations · 2025-11-25 on roughly 45 branches. Today: “We put a plan to have 50 branches in three years.” — Hend El Sherbini, Chief Executive Officer · 2026-09-15 Biolab KSA revenue grew 191% to SAR 5.5m off five Riyadh branches, with Jeddah and the Eastern Province next. That is Saudi Arabia shifting from option to committed capital program.

Following this review, the board considers it prudent to preserve cash and maintain balance sheet flexibility. This will reflect both a number of well-defined expansion opportunities that we have on hand currently and the continued, of course, geopolitical uncertainty that is going in the region.
Mirette Ahmed, Investment Section Head and Investor Relations Officer · 2026-09-15

The Cash Call: A Dividend That Didn't Happen

This is the tension in the story. Cash generation is robust, yet the dividend distribution keyword now sits against a decision not to pay. Recall that as recently as last autumn, returning capital was the celebrated move; by April, management was even floating a buyback. Now the answer is cash preservation — and the balance sheet shows why the optics are mixed. Net cash fell to EGP 239m from EGP 472m at year-end, inventory planning pushed days-of-inventory to 119 from 94, receivables stretched to 131 days, and interest expense stayed elevated on the Cairo Ray acquisition debt. Analysts pressed on exactly this, and got expansion optionality plus regional risk as the answer. Two under-noticed details sharpen the picture. First, Nigeria recorded its first positive net income (NGN 35m) after a 12% local-currency revenue rise and EBITDA margin improving to 7% from 2% — a turnaround that is now genuinely self-funding and needs no new branches. Second, pricing: after a 4% Q2 increase, “We are not planning to do any price increase for the rest of the year.” — Hend El Sherbini, Chief Executive Officer · 2026-09-15 Volume and mix, not price, must carry H2.

What's Genuinely New, and What's Boilerplate

The freshest company keyword is procurement optimization, which tops IDH's current cross-section and is doing real work — COGS fell to 56.7% of revenue. Alongside a newly prominent branch network narrative and disciplined cost management, these are the mechanical drivers behind the margin upgrade. They also rhyme with the global market's current obsession with earnings growth and margin resilience — but IDH is not riding a sector wave; diagnostics demand in Egypt, Jordan and Saudi is idiosyncratic, and no global theme cluster (tariff refunds, AI infrastructure, data-center power) maps onto this name. The honest read: the dividend reversal and working-capital build are watch items, but a company that raises its own EBITDA guide by three-to-four points while accelerating Saudi from five branches to a fifty-branch target is not standing still. The next print has to prove the 37% margin is a floor, not a peak.